Rituximab

Non-Hodgkin lymphoma (including DLBCL, follicular lymphoma, marginal zone lymphoma); Chronic lymphocytic leukemia (CLL) in combination with chemotherapy; Rheumatoid arthritis; Granulomatosis with polyangiitis. Note: Available as biosimilar rituximab-pvvr (Ruxience), rituximab-abbs (Truxima), and rituximab-arrx (Riabni).

NHL: 375 mg/m² IV infusion per cycle. CLL: 375 mg/m² cycle 1, 500 mg/m² cycles 2-6. Premedicate with acetaminophen and diphenhydramine.

Fatal Infusion Reactions: Premedicate and monitor. Tumor Lysis Syndrome: Monitor and prophylax. Severe Mucocutaneous Reactions: Stevens-Johnson syndrome reported. Progressive Multifocal Leukoencephalopathy (PML): JC virus reactivation. Hepatitis B Reactivation.

Infusion reactions (77%), fever (53%), chills (33%), infection (31%), asthenia (26%), nausea (23%), headache (19%), angioedema (11%)

Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.

Rituximab is a chimeric monoclonal antibody targeting CD20, a cell-surface antigen expressed on pre-B and mature B lymphocytes and most B-cell lymphomas. Binding triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct apoptosis induction in CD20-expressing tumor cells.

Half-life: 22 days. Route: IV. Refer to the full prescribing information for complete pharmacokinetic data.

Clinical efficacy and safety data are available in the full prescribing information and referenced publications.